Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
267 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cystic Fibrosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H2 2014', provides an overview of the Cystic Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Cystic Fibrosis Overview 11 Therapeutics Development 12 Pipeline Products for Cystic Fibrosis - Overview 12 Pipeline Products for Cystic Fibrosis - Comparative Analysis 13 Cystic Fibrosis - Therapeutics under Development by Companies 14 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 18 Cystic Fibrosis - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Cystic Fibrosis - Products under Development by Companies 24 Cystic Fibrosis - Products under Investigation by Universities/Institutes 29 Cystic Fibrosis - Companies Involved in Therapeutics Development 30 Alaxia SAS 30 AlgiPharma AS 31 Bayer AG 32 Beech Tree Labs, Inc. 33 Carolus Therapeutics, Inc. 34 Celsus Therapeutics Plc 35 Celtaxsys, Inc. 36 Chiesi Farmaceutici SpA 37 Cilian AG 38 Concert Pharmaceuticals, Inc. 39 Corbus pharmaceuticals, Inc. 40 Cubist Pharmaceuticals, Inc. 41 DiscoveryBiomed, Inc. 42 Errant Gene Therapeutics, LLC 43 Galapagos NV 44 GlaxoSmithKline plc 45 Grifols, S.A. 46 Harbor Therapeutics, Inc. 47 Invion Limited 48 InvivoGen Therapeutics 49 JHL Biotech, Inc. 50 Kamada Ltd. 51 Lamellar Biomedical Ltd 52 Laurent Pharmaceuticals Inc. 53 Microbion Corporation 54 Mucokinetica Ltd. 55 N30 Pharmaceuticals 56 NanoBio Corporation 57 Nostrum Pharmaceuticals, LLC 58 Novabiotics Ltd 59 Novartis AG 60 Ockham Biotech Limited 61 OSE Pharma SA 62 PARI Pharma GmbH 63 Parion Sciences, Inc. 64 Pfizer Inc. 65 Pharmaxis Limited 66 Polyphor Ltd. 67 Progenra, Inc. 68 ProQR Therapeutics N.V. 69 Protalix BioTherapeutics, Inc. 70 PTC Therapeutics, Inc. 71 Pulmatrix, Inc. 72 Reata Pharmaceuticals, Inc. 73 ReveraGen BioPharma, Inc. 74 Serendex Pharmaceuticals A/S 75 Synovo GmbH 76 Verona Pharma Plc 77 Vertex Pharmaceuticals Incorporated 78 Xenetic Biosciences plc 79 Cystic Fibrosis - Therapeutics Assessment 80 Assessment by Monotherapy Products 80 Assessment by Combination Products 81 Assessment by Target 82 Assessment by Mechanism of Action 85 Assessment by Route of Administration 88 Assessment by Molecule Type 90 Drug Profiles 92 (fosfomycin + tobramycin) - Drug Profile 92 alpha-1-proteinase inhibitor (human) - Drug Profile 93 ALX-009 - Drug Profile 97 Anti-Microbial Drug for Cystic Fibrosis - Drug Profile 99 ataluren - Drug Profile 100 BTL-na - Drug Profile 103 CFX-1 - Drug Profile 104 CSY-0073 - Drug Profile 105 CT-2009 - Drug Profile 106 CTX-4430 - Drug Profile 107 cysteamine - Drug Profile 109 D-Ivacaftor - Drug Profile 111 dapsone - Drug Profile 112 Deoxyribonuclease II to Target DNA for Cystic Fibrosis - Drug Profile 113 dornase alfa biosimilar - Drug Profile 114 Drug for Cystic Fibrosis - Drug Profile 115 Drug to Activate Kir 4.2 for Cystic Fibrosis - Drug Profile 116 Drugs for COPD and Cystic Fibrosis - Drug Profile 117 Drugs for Cystic Fibrosis and COPD - Drug Profile 118 Drugs for Cystic Fibrosis Lung Infections - Drug Profile 119 FDL-169 - Drug Profile 120 fenretinide - Drug Profile 121 fosfomycin - Drug Profile 122 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 123 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 124 GLPG-1837 - Drug Profile 125 GSK-2225745 - Drug Profile 127 HE-3286 - Drug Profile 128 Heparin - Drug Profile 130 JBT-101 - Drug Profile 132 levofloxacin - Drug Profile 133 LMS-611 - Drug Profile 134 lumacaftor - Drug Profile 135 mannitol - Drug Profile 138 MKA-104 - Drug Profile 141 molgramostim - Drug Profile 142 N-1785 - Drug Profile 143 N-1861 - Drug Profile 144 N-6022 - Drug Profile 145 N-6547 - Drug Profile 146 N-91115 - Drug Profile 147 N-91138 - Drug Profile 148 N-91169 - Drug Profile 149 nadolol - Drug Profile 150 NB-401 - Drug Profile 151 Next Generation Correctors - Drug Profile 152 nitric oxide - Drug Profile 153 nitric oxide - Drug Profile 154 Oligomer G for Cystic Fibrosis - Drug Profile 155 ORP-100 - Drug Profile 157 P-1037 - Drug Profile 158 Peptide to Block ENaC for Cystic Fibrosis and Hypertension - Drug Profile 159 PN-1 - Drug Profile 160 POL-6014 - Drug Profile 161 PRX-110 - Drug Profile 163 pseudomonas aeruginosa vaccine - Drug Profile 164 PulmoXen - Drug Profile 165 PUR-1000 - Drug Profile 166 PUR-118 - Drug Profile 167 PXS-4728A - Drug Profile 168 QBW-251 - Drug Profile 169 QR-010 - Drug Profile 170 Recombinant A1PI - Drug Profile 171 Recombinant Enzyme for Cystic Fibrosis - Drug Profile 172 Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Drug Profile 173 Recombinant Human Follistatin - Drug Profile 174 Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile 175 riociguat - Drug Profile 176 RPL-554 - Drug Profile 178 Small Molecule for Cystic Fibrosis - Drug Profile 180 Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 181 Small Molecule for Respiratory Disorders - Drug Profile 182 Small Molecule to Activate CFTR Protein for Cystic Fibrosis - Drug Profile 183 Small Molecule to Activate Nrf2 for Cystic Fibrosis - Drug Profile 184 Small Molecule to Inhibit EnaC and Activate CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 185 Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile 186 Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile 187 Small Molecules for Cystic Fibrosis - Drug Profile 188 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 189 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 190 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 191 Small Molecules to Inhibit Neutrophil Elastases - Drug Profile 192 Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile 193 solithromycin - Drug Profile 194 SP-14 - Drug Profile 196 SP-9 - Drug Profile 197 tritoqualine - Drug Profile 198 VBP-15 - Drug Profile 199 VRT-325 - Drug Profile 201 VX-661 - Drug Profile 202 Cystic Fibrosis - Recent Pipeline Updates 203 Cystic Fibrosis - Dormant Projects 243 Cystic Fibrosis - Discontinued Products 249 Cystic Fibrosis - Product Development Milestones 250 Featured News & Press Releases 250 Appendix 260 Methodology 260 Coverage 260 Secondary Research 260 Primary Research 260 Expert Panel Validation 260 Contact Us 261 Disclaimer 261
List of Tables Number of Products under Development for Cystic Fibrosis, H2 2014 18 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2014 25 Comparative Analysis by Late Stage Development, H2 2014 26 Comparative Analysis by Clinical Stage Development, H2 2014 27 Comparative Analysis by Early Stage Development, H2 2014 28 Comparative Analysis by Unknown Stage Development, H2 2014 29 Products under Development by Companies, H2 2014 30 Products under Development by Companies, H2 2014 (Contd..1) 31 Products under Development by Companies, H2 2014 (Contd..2) 32 Products under Development by Companies, H2 2014 (Contd..3) 33 Products under Development by Companies, H2 2014 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2014 35 Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2014 36 Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2014 37 Cystic Fibrosis - Pipeline by Bayer AG, H2 2014 38 Cystic Fibrosis - Pipeline by Beech Tree Labs, Inc., H2 2014 39 Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2014 40 Cystic Fibrosis - Pipeline by Celsus Therapeutics Plc, H2 2014 41 Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2014 42 Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2014 43 Cystic Fibrosis - Pipeline by Cilian AG, H2 2014 44 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 45 Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H2 2014 46 Cystic Fibrosis - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 47 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2014 48 Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H2 2014 49 Cystic Fibrosis - Pipeline by Galapagos NV, H2 2014 50 Cystic Fibrosis - Pipeline by GlaxoSmithKline plc, H2 2014 51 Cystic Fibrosis - Pipeline by Grifols, S.A., H2 2014 52 Cystic Fibrosis - Pipeline by Harbor Therapeutics, Inc., H2 2014 53 Cystic Fibrosis - Pipeline by Invion Limited, H2 2014 54 Cystic Fibrosis - Pipeline by InvivoGen Therapeutics, H2 2014 55 Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H2 2014 56 Cystic Fibrosis - Pipeline by Kamada Ltd., H2 2014 57 Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2014 58 Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H2 2014 59 Cystic Fibrosis - Pipeline by Microbion Corporation, H2 2014 60 Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H2 2014 61 Cystic Fibrosis - Pipeline by N30 Pharmaceuticals, H2 2014 62 Cystic Fibrosis - Pipeline by NanoBio Corporation, H2 2014 63 Cystic Fibrosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2014 64 Cystic Fibrosis - Pipeline by Novabiotics Ltd, H2 2014 65 Cystic Fibrosis - Pipeline by Novartis AG, H2 2014 66 Cystic Fibrosis - Pipeline by Ockham Biotech Limited, H2 2014 67 Cystic Fibrosis - Pipeline by OSE Pharma SA, H2 2014 68 Cystic Fibrosis - Pipeline by PARI Pharma GmbH, H2 2014 69 Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H2 2014 70 Cystic Fibrosis - Pipeline by Pfizer Inc., H2 2014 71 Cystic Fibrosis - Pipeline by Pharmaxis Limited, H2 2014 72 Cystic Fibrosis - Pipeline by Polyphor Ltd., H2 2014 73 Cystic Fibrosis - Pipeline by Progenra, Inc., H2 2014 74 Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H2 2014 75 Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 76 Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H2 2014 77 Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H2 2014 78 Cystic Fibrosis - Pipeline by Reata Pharmaceuticals, Inc., H2 2014 79 Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H2 2014 80 Cystic Fibrosis - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 81 Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2014 82 Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2014 83 Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 84 Cystic Fibrosis - Pipeline by Xenetic Biosciences plc, H2 2014 85 Assessment by Monotherapy Products, H2 2014 86 Assessment by Combination Products, H2 2014 87 Number of Products by Stage and Target, H2 2014 89 Number of Products by Stage and Mechanism of Action, H2 2014 92 Number of Products by Stage and Route of Administration, H2 2014 95 Number of Products by Stage and Molecule Type, H2 2014 97 Cystic Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 209 Cystic Fibrosis - Dormant Projects, H2 2014 249 Cystic Fibrosis - Dormant Projects (Contd..1), H2 2014 250 Cystic Fibrosis - Dormant Projects (Contd..2), H2 2014 251 Cystic Fibrosis - Dormant Projects (Contd..3), H2 2014 252 Cystic Fibrosis - Dormant Projects (Contd..4), H2 2014 253 Cystic Fibrosis - Dormant Projects (Contd..5), H2 2014 254 Cystic Fibrosis - Discontinued Products, H2 2014 255
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
